Zura Bio (NASDAQ:ZURA) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Zura Bio (NASDAQ:ZURA) in a report released on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $15.00 price target on the stock.

Several other equities research analysts also recently issued reports on ZURA. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Finally, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a report on Monday, October 21st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $16.75.

Zura Bio Stock Up 4.6 %

Shares of Zura Bio stock opened at $4.30 on Monday. The business has a fifty day simple moving average of $4.17 and a two-hundred day simple moving average of $4.09. Zura Bio has a 1 year low of $2.00 and a 1 year high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sell-side analysts predict that Zura Bio will post -0.47 EPS for the current year.

Insider Transactions at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the sale, the director now owns 2,085,418 shares of the company’s stock, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ZURA. Affinity Asset Advisors LLC bought a new position in shares of Zura Bio in the first quarter worth $1,157,000. Bank of New York Mellon Corp grew its position in Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the last quarter. Renaissance Technologies LLC grew its position in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after acquiring an additional 5,900 shares during the last quarter. Great Point Partners LLC grew its position in Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares during the last quarter. Finally, Armistice Capital LLC grew its position in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.